Profile data is unavailable for this security.
About the company
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.
- Revenue in USD (TTM)13.00k
- Net income in USD-48.07m
- Incorporated2002
- Employees20.00
- LocationAyala Pharmaceuticals Inc9 DEER PARK DRIVE, SUITE K-1MONMOUTH JUNCTION 08852United StatesUSA
- Phone+1 (732) 545-1590
- Fax+1 (302) 674-5266
- Websitehttps://ayalapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 22.42m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Lumos Pharma Inc | 2.05m | -34.03m | 22.48m | 33.00 | -- | 0.822 | -- | 10.96 | -4.19 | -4.19 | 0.2526 | 3.37 | 0.0363 | -- | 9.47 | 62,151.52 | -60.27 | -29.78 | -68.62 | -32.32 | -- | -- | -1,659.39 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Zivo Bioscience Inc | 27.65k | -7.78m | 22.50m | 8.00 | -- | -- | -- | 813.70 | -4.62 | -4.62 | 0.0163 | -0.9259 | 0.0206 | -- | -- | 3,456.25 | -580.66 | -376.60 | -- | -- | 41.99 | -- | -28,127.23 | -96,315.32 | -- | -97.39 | -- | -- | -- | -- | 11.07 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -23.96m | 22.51m | 5.00 | -- | 1.90 | -- | -- | -1.50 | -1.50 | 0.00 | 0.7435 | 0.00 | -- | -- | 0.00 | -88.71 | -- | -102.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Biora Therapeutics Inc | 4.00k | -124.33m | 22.52m | 58.00 | -- | -- | -- | 5,631.07 | -8.57 | -8.56 | 0.0003 | -4.28 | 0.00009 | -- | 0.0048 | 68.97 | -293.45 | -122.84 | -- | -369.01 | -- | -- | -3,108,350.00 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Polypid Ltd | 0.00 | -23.87m | 22.80m | 59.00 | -- | -- | -- | -- | -19.44 | -19.44 | 0.00 | -1.27 | 0.00 | -- | -- | 0.00 | -115.45 | -76.92 | -187.15 | -89.61 | -- | -- | -- | -- | -- | -24.61 | 1.25 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.36m | 22.85m | 4.00 | -- | 6.84 | -- | 351.46 | -0.9042 | -0.9042 | 0.0108 | 0.4253 | 0.0455 | -- | -- | 16,250.00 | -374.94 | -- | -- | -- | 92.00 | -- | -8,239.82 | -- | -- | -67.87 | 0.00 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Serina Therapeutics Inc | 142.00k | -14.80m | 22.98m | 4.00 | -- | 1.81 | -- | 161.86 | -13.72 | -13.72 | 0.1316 | 5.07 | 0.0187 | -- | 4.66 | 35,500.00 | -194.80 | -194.46 | -- | -- | 71.83 | 85.80 | -10,430.28 | -2,347.36 | -- | -2.03 | 0.4489 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 23.66m | 20.00 | -- | -- | -- | 1,820.12 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| Oncternal Therapeutics Inc | 785.00k | -39.48m | 24.54m | 27.00 | -- | 0.8132 | -- | 31.26 | -13.44 | -13.44 | 0.2672 | 10.19 | 0.0149 | -- | -- | 29,074.07 | -74.93 | -49.40 | -85.36 | -54.51 | -- | -- | -5,029.17 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.55m | -27.24m | 24.78m | 36.00 | -- | 0.6413 | -- | 15.95 | -1.02 | -1.02 | 0.0574 | 1.39 | 0.0338 | -- | 0.3774 | 43,166.67 | -59.27 | -31.60 | -64.80 | -35.49 | -- | -- | -1,752.77 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Cumberland Pharmaceuticals, Inc. | 39.55m | -6.28m | 24.95m | 91.00 | -- | 0.8396 | -- | 0.6308 | -0.4448 | -0.4448 | 2.75 | 2.10 | 0.4528 | 0.8383 | 3.45 | 434,643.10 | -7.25 | -7.03 | -10.66 | -9.52 | 84.66 | 79.95 | -16.01 | -17.64 | 1.11 | -25.08 | 0.3041 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Yubo International Biotech Ltd | 604.68k | -1.20m | 25.16m | 18.00 | -- | -- | -- | 41.61 | -0.01 | -0.01 | 0.005 | -0.0154 | 0.3012 | 0.6912 | 9.19 | 33,593.33 | -59.52 | -- | -- | -- | 69.32 | -- | -197.64 | -- | 0.1504 | -3,143.97 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Unity Biotechnology Inc | 0.00 | -39.86m | 25.18m | 19.00 | -- | 0.8866 | -- | -- | -2.75 | -2.75 | 0.00 | 1.69 | 0.00 | -- | -- | 0.00 | -41.95 | -47.21 | -49.03 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
Data as of Apr 26 2024. Currency figures normalised to Ayala Pharmaceuticals Inc's reporting currency: US Dollar USD
0.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Dec 2023 | 123.56k | 0.29% |
| State of Wisconsin Investment Boardas of 31 Dec 2017 | 22.00 | 0.00% |
| Wellington Management Co. LLPas of 30 Dec 2022 | 0.00 | 0.00% |
| Welzia Management SGIIC SAas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
